🔓 Unlock the full profile of Thomas Gad (Y-Mabs Therapeutics, Inc.), including verified contact details, financial insights, and professional associations.
See Thomas Gad Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: tho*****@y-m******.com
Mobile: 94684*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Thomas Gad is the Founder, Vice Chair, and Chief Business Officer of Y-mAbs Therapeutics, Inc., which was established in April 2015 to develop innovative antibody-based therapies for cancer treatment.
- Y-mAbs Therapeutics focuses on the development of monoclonal antibody therapies, particularly for pediatric patients with cancer, addressing significant unmet medical needs in the oncology field.
- The company has achieved notable progress in clinical trials, with developmental candidates like omburtamab and naxitamab showing promise in treating neuroblastoma and other cancers.
- Under Thomas Gad's leadership, Y-mAbs Therapeutics was publicly listed on NASDAQ under the symbol 'YMAB', providing a platform for greater investment and growth opportunities.
- Y-mAbs Therapeutics has garnered a market capitalization of approximately $182.7 million, reflecting investor confidence and the potential of its therapeutic offerings.
- The organization has experienced a significant increase in headcount, with a 41.5% growth over the past two years, indicating expansion and diversification of its operational capabilities.
- Thomas Gad actively engages in strategic partnerships and collaborations, enabling Y-mAbs Therapeutics to enhance its research, development, and commercial efforts.
- The commitment to addressing pediatric cancers distinguishes Y-mAbs Therapeutics and underscores Thomas Gad's focus on making impactful contributions to healthcare and patient outcomes.